Dr. Martens (LON:DOCS) Insider Buys £149.76 in Stock

Dr. Martens plc (LON:DOCS) insider Giles Wilson purchased 192 shares of the business’s stock in a transaction dated Tuesday, January 13th. The stock was bought at an average price of GBX 78 per share, for a total transaction of £149.76.

Giles Wilson also recently made the following trade(s):

• On Thursday, December 11th, Giles Wilson acquired 197 shares of Dr. Martens stock. The shares were bought at an average price of GBX 76 per share, with a total value of £149.72.
• On Tuesday, November 11th, Giles Wilson bought 176 shares of Dr. Martens stock. The stock was bought at an average price of GBX 85 per share, for a total transaction of £149.60.

Dr. Martens Price Performance

Shares of DOCS stock opened at GBX 75.70 on Friday. The company has a market capitalization of £731.69 million, a P/E ratio of 44.53, a P/E/G ratio of 6.40 and a beta of 0.11. The company’s 50-day simple moving average is GBX 77.72 and its two-hundred day simple moving average is GBX 83.50. The company has a debt-to-equity ratio of 127.27, a current ratio of 2.85 and a quick ratio of 1.13. Dr. Martens plc has a one year low of GBX 43.02 and a one year high of GBX 100.87.

Dr. Martens (LON:DOCS) last posted its quarterly earnings data on Thursday, November 20th. The company reported GBX (0.90) EPS for the quarter. Dr. Martens had a net margin of 7.89% and a return on equity of 18.91%. As a group, equities analysts anticipate that Dr. Martens plc will post 2.5809394 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Peel Hunt reiterated a “buy” rating on shares of Dr. Martens in a research report on Thursday, November 20th. Berenberg Bank reaffirmed a “buy” rating on shares of Dr. Martens in a research note on Thursday, November 27th. Two analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, Dr. Martens presently has a consensus rating of “Moderate Buy” and an average target price of GBX 6,000.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.